ly3437943 retatrutide triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Efficacy and safety of retatrutide,

Currently enrolling clinical trials (T1-DISCO and Obesity Complicating T1D: GLP-1 Analogue Anti-Obesity Treatment) in young adults living with T1D and obesity are investigating the impacts of GLP-1s on cardiovascular outcomes

Phosphorylation of eIF2 by PERK in response to ER stress decreases translation of mRNA and reduces stress (Harding et al , 2003)

Leaf inoculation with the avirulent island-carrying strain Pph 1302A triggered effector-triggered immunity (ETI), resulting in distinct alterations in apoplast composition

Other biomarkers measured by the research team including blood pressure, heart rate, hypoglycemic episodes, fasting glucagon, fasting serum insulin, high-sensitivity C-reactive protin, leptin, and a general lipid panal